Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

amneal pharmaceuticals - AMRX

AMRX

Close Chg Chg %
8.10 -0.18 -2.22%

Closed Market

7.92

-0.18 (2.22%)

Volume: 620.53K

Last Updated:

Dec 12, 2024, 4:00 PM EDT

Trade Now

Company Overview: amneal pharmaceuticals - AMRX

AMRX Key Data

Open

$8.03

 Day Range

7.90 - 8.16

52 Week Range

4.46 - 9.47

 Market Cap

$2.51B

Shares Outstanding

309.84M

 Public Float

126.70M

Beta

1.12

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.68

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.18M

  

AMRX Performance

1 Week
 
 -6.27%
 
1 Month
 
 -6.49%
 
3 Months
 
 -8.12%
 
1 Year
 
 52.60%
 
5 Years
 
 66.39%
 

AMRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 4
Full Ratings ➔

About amneal pharmaceuticals - AMRX

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

AMRX At a Glance

Amneal Pharmaceuticals, Inc.
400 Crossing Boulevard
Bridgewater, New Jersey 08807
Phone 1-908-947-3120 Revenue 2.39B
Industry Pharmaceuticals: Major Net Income -83,993,000.00
Sector Health Technology 2023 Sales Growth 8.195%
Fiscal Year-end 12 / 2024 Employees 7,850
View SEC Filings

AMRX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.447
Price to Book Ratio 94.079
Price to Cash Flow Ratio 5.837
Enterprise Value to EBITDA 7.64
Enterprise Value to Sales 1.572
Total Debt to Enterprise Value 0.731

AMRX Efficiency

Revenue/Employee 304,918.089
Income Per Employee -10,699.745
Receivables Turnover 3.707
Total Asset Turnover 0.658

AMRX Liquidity

Current Ratio 1.628
Quick Ratio 0.941
Cash Ratio 0.117

AMRX Profitability

Gross Margin 35.79
Operating Margin 10.989
Pretax Margin -1.682
Net Margin -3.509
Return on Assets -2.31
Return on Equity -52.792
Return on Total Capital -3.032
Return on Invested Capital -3.01

AMRX Capital Structure

Total Debt to Total Equity 13,904.873
Total Debt to Total Capital 99.286
Total Debt to Total Assets 79.207
Long-Term Debt to Equity 12,754.153
Long-Term Debt to Total Capital 91.069
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Amneal Pharmaceuticals - AMRX

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
1.99B 2.09B 2.21B 2.39B
Sales Growth
+22.51% +5.08% +5.67% +8.20%
Cost of Goods Sold (COGS) incl D&A
1.33B 1.30B 1.42B 1.54B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
235.39M 233.41M 240.18M 229.40M
Depreciation
60.42M 60.70M 68.11M 66.20M
Amortization of Intangibles
174.97M 172.70M 172.06M 163.20M
COGS Growth
+15.89% -2.07% +8.79% +8.50%
Gross Income
662.97M 791.66M 795.82M 856.66M
Gross Income Growth
+38.36% +19.41% +0.52% +7.65%
Gross Profit Margin
+33.27% +37.81% +35.97% +35.79%
2020 2021 2022 2023 5-year trend
SG&A Expense
506.66M 567.35M 595.39M 593.63M
Research & Development
179.93M 201.85M 195.69M 163.95M
Other SG&A
326.73M 365.50M 399.70M 429.68M
SGA Growth
+6.07% +11.98% +4.94% -0.30%
Other Operating Expense
- - - -
-
Unusual Expense
65.16M 71.60M 299.61M 100.61M
EBIT after Unusual Expense
91.16M 152.72M (99.18M) 162.43M
Non Operating Income/Expense
19.06M 14.97M 9.43M 7.93M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
146.00M 136.32M 158.38M 210.63M
Interest Expense Growth
-13.20% -6.63% +16.18% +32.99%
Gross Interest Expense
146.00M 136.32M 158.38M 210.63M
Interest Capitalized
- - - -
-
Pretax Income
(35.78M) 31.37M (248.13M) (40.27M)
Pretax Income Growth
+83.75% +187.66% -891.07% +83.77%
Pretax Margin
-1.80% +1.50% -11.22% -1.68%
Income Tax
(104.36M) 11.20M 6.66M 8.45M
Income Tax - Current - Domestic
(113.75M) 1.31M (1.07M) 2.47M
Income Tax - Current - Foreign
9.40M 9.88M 7.74M 5.98M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
68.58M 20.17M (254.79M) (48.72M)
Minority Interest Expense
(22.48M) 9.55M (124.80M) 35.27M
Net Income
91.06M 10.62M (129.99M) (83.99M)
Net Income Growth
+125.16% -88.33% -1,323.51% +35.38%
Net Margin Growth
+4.57% +0.51% -5.88% -3.51%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
91.06M 10.62M (129.99M) (83.99M)
Preferred Dividends
- - - -
-
Net Income Available to Common
91.06M 10.62M (129.99M) (83.99M)
EPS (Basic)
0.6176 0.0713 -0.8612 -0.4769
EPS (Basic) Growth
+122.54% -88.46% -1,307.85% +44.62%
Basic Shares Outstanding
147.44M 148.92M 150.94M 176.14M
EPS (Diluted)
0.6115 0.07 -0.8612 -0.4769
EPS (Diluted) Growth
+122.32% -88.55% -1,330.29% +44.62%
Diluted Shares Outstanding
148.91M 151.82M 150.94M 176.14M
EBITDA
391.70M 457.72M 440.61M 492.44M
EBITDA Growth
+87.64% +16.85% -3.74% +11.76%
EBITDA Margin
+19.66% +21.86% +19.92% +20.57%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 10.00
Number of Ratings 4 Current Quarters Estimate 0.151
FY Report Date 12 / 2024 Current Year's Estimate 0.613
Last Quarter’s Earnings 0.16 Median PE on CY Estimate N/A
Year Ago Earnings 0.64 Next Fiscal Year Estimate 0.728
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 3 4 4
Mean Estimate 0.15 0.17 0.61 0.73
High Estimates 0.16 0.21 0.63 0.82
Low Estimate 0.14 0.14 0.60 0.57
Coefficient of Variance 8.07 21.49 2.45 15.32

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 1 1 1
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Amneal Pharmaceuticals - AMRX

Date Name Shares Transaction Value
Nov 26, 2024 Deborah M. Autor Director 53,402 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.34 per share 445,372.68
Nov 26, 2024 Deborah M. Autor Director 86,631 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.41 per share 728,566.71
May 15, 2024 Emily Peterson Alva Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Shlomo Yanai Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Shlomo Yanai Director 245,727 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Paul M. Meister Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Paul M. Meister Director 727,692 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 J. Kevin Buchi Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 J. Kevin Buchi Director 262,072 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Ted C. Nark Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Ted C. Nark Director 300,771 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 John J. Kiely Director 255,727 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Jeffrey P. George Director 269,537 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Emily Peterson Alva Director 250,771 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Gautam Patel Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 John J. Kiely Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Jeffrey P. George Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 15, 2024 Gautam Patel Director 2,048,886 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 15, 2024 Anastasios G. Konidaris Executive Vice President & CFO 527,316 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $5.31 per share 2,800,047.96
Mar 15, 2024 Anastasios G. Konidaris Executive Vice President & CFO 558,106 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Amneal Pharmaceuticals in the News